Noting in our RNA-sequencing data that the median DLL3 expression level in neuroblastomas was higher than in SCLC, here we sought to develop DLL3 as an immunotherapeutic target for high-risk neuroblastoma. Here, DLL3 is linked to neuroblastoma.